| Objective: By detection the expression of the Excision repair crosscomplementing1(ERCC1), Topoisomerase Ⅱ (TopoⅡα) and Ki67in small cell lungcancer (SCLC),to explore its correlation with prognosis,and the correlation among thesethree genes, and to provide a theoretical basis for exploring the SCLC molecularmarkers.Materials and methods:1.Collection2004-2010for treatment in the First Affiliated Hospital of DalianMedical University,212cases of small cell lung cancer, and excluding the outer courtconfirmed cases, small pathological paraffin specimens or lost,to the eventualinclusion in41cases,30patients had imited disease (LD) and11had extensive disease(ED).41patients were treated with cisplatin combined with etoposide program ofchemotherapy, which LD patients receiving that thoracic irradiation was performedeither concurrently with chemotherapy or sequentially.2.The expression of ERCC1,TopoⅡα and Ki67were determined byimmunohistochemistry in the paraffin—embedded tumor specimens of the41specimens.3.SPSS17.0statistical software was used for statistical analysis，prognostic factorswere evaluated by univariate analyses；the proportions between the expression ofERCC1,TopoⅡα,Ki67and clinical character was compared by Chi-square test；survivalcurves were produced and median survival times were estimated using the method ofKaplan—Meier. Comparisons of the survival curves of groups were based on thelog—rank test；Cox proportional hazards regression was used for multivariate analysis；to explore the association between ERCC1,TopoⅡα and Ki67using Spearman analysis. Results:1.The positive expression rates of ERCC1,TopoⅡα in the SCLC tissue were32%,68%；Expression of Ki67in the SCLC tissue, low, medium and high expressionrates were44%,37%,19%;2.Association of expression of ERCC1、TopoⅡα and Ki67with clinical character：The expression of ERCC1and TopoⅡα is no statistically significant differencewith sex,age,smoking index,decline (≥5%),ECOG score and tumor clinical stage(P>0.05).The expression of Ki67is no statistically significant difference withsex,age,smoking index, decline (≥5%)and ECOG score (P>0.05), but it is statisticallysignificant difference with tumor clinical stage (P <0.05).3.Association of expression of ERCC1、TopoⅡα and Ki67with survival：High expression of ERCC1was significantly correlated with poor outcome(mediansurvival25months vs.9months, P <0.01), In limited stage patients, low expression ofERCC1had significantly longer survival than the high expression (median survival30months vs.8months, P <0.01);TopoⅡα negative expression had a better survival benefit than the positiveexpression (median survival of25months vs.13months, P <0.05); about PFS, lowerexpression of TopoⅡα was associated to a better survival than high expression in LDpatients (median survival25months vs.21months, P <0.05);Ki67expression in survival compared to high expression extend (30monthsvs.18months vs.12months), the difference was statistically significant (P <0.01);4.Ki67was correlated significantly with both ERCC1and TopoⅡα (P <0.05);theexpression of ERCC1and TopoⅡα had no correlation (P>0.05).5.Multivariate Cox regression analysis showed that sex,ERCC1,Ki67and clinicalstage were independent prognostic factors of SCLC.Conclusion:1.Association of expression of ERCC1、TopoⅡα and Ki67with clinical character：The expression of ERCC1and TopoⅡα is no statistically significant differencewith sex,age,smoking index,decline (≥5%),ECOG score and tumor clinical stage.The expression of Ki67is no statistically significant difference Withsex,age,smoking index, decline (≥5%)and ECOG score, but it is statistically significantdifference with tumor clinical stage.2.Association of expression of ERCC1、TopoⅡα and Ki67with survival： ERCC1-negative expression, TopoⅡα negative expression and Ki67lowexpression in SCLC had a survival benefit.3.Ki67was correlated significantly with both ERCC1and TopoⅡα;The expressionof ERCC1and TopoⅡα had no correlation.4.ERCC1and Ki67could be assessment of the significant prognostic indicators. |
PDF Full Text Request